RxDoctor Payments Data

Robert Johnson, MD

Family Medicine · Pendleton, ORNPI 1104846351

Payments from drug & device makers

$760in general payments, 2019–2025

Across 55 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$251
  • Amgen$93
  • Boehringer Ingelheim$68
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$63
  • Takeda Pharmaceuticals U.S.A., Inc.$40
  • Lilly USA, LLC$36
  • plus $209 from 11 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$760 in reported general payments places this provider in the 85th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$6,262
Medicare patients
40
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$83,426
OzempicSemaglutide58$67,771
TrulicityDulaglutide37$42,918
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$39,016
JardianceEmpagliflozin45$37,107
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$27,278
JanuviaSitagliptin Phosphate28$23,421
XareltoRivaroxaban14$20,022
FarxigaDapagliflozin Propanediol12$14,184
TradjentaLinagliptin14$8,867
Incruse ElliptaUmeclidinium Bromide15$8,062
VascepaIcosapent Ethyl11$7,560
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$7,144
BelsomraSuvorexant12$5,532
Atorvastatin Calcium353$4,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$251$67,77158 claims
GSKTrelegy Ellipta, Incruse Ellipta$23$47,07760 claims
Boehringer IngelheimJardiance, Tradjenta$68$45,97459 claims
Lilly USA, LLCTrulicity$36$42,91837 claims
MerckJanuvia, Belsomra$27$28,95440 claims
AstraZenecaFarxiga$23$14,18412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Pendleton

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →